PridCor Therapeutics Secures Global Antiviral Portfolio

PridCor Therapeutics Acquires Global Antiviral Portfolio for Long COVID

PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, announced the acquisition of a global antiviral asset portfolio. This strategic move positions PridCor as a leader in developing treatments for Long COVID and a broad range of infection-associated chronic illnesses (IACI). The portfolio includes IMC-2, a Phase 2b-ready fixed-dose combination targeting the full spectrum of Long COVID symptoms, and IMC-1, a Phase 3-ready candidate for fibromyalgia. This acquisition significantly expands PridCor's clinical pipeline, establishing one of the most advanced and comprehensive antiviral pipelines targeting viral reactivation, a key underlying driver across multiple chronic disease states.

• Strategic Asset Acquisition: PridCor Therapeutics has acquired a comprehensive global antiviral asset portfolio, featuring IMC-2, a Phase 2b-ready fixed-dose combination designed to address the full spectrum of Long COVID symptoms and related chronic conditions like ME/CFS, fibromyalgia, and IBS. The portfolio also includes IMC-1, a Phase 3-ready candidate specifically for fibromyalgia, providing a late-stage asset for rapid clinical advancement.
• Leadership in Chronic Illness Treatment: This acquisition establishes PridCor as a leading developer of treatments for Long COVID and a broad range of infection-associated chronic illnesses (IACI). The company aims to address a significant unmet medical need by targeting viral reactivation, which is increasingly recognized as an underlying driver across various chronic disease states, thereby building a category-defining company in this emerging healthcare challenge.
• Clinical Validation and Pipeline Expansion: PridCor is advancing its proprietary combination antiviral regimen into the Icahn School of Medicine at Mount Sinai’s SHIELD study, building on recently published Long COVID case series. This collaboration further validates their approach. The acquisition significantly expands PridCor's clinical pipeline, strengthening its scientific foundation and positioning it as a central platform for developing multi-mechanism antiviral therapies.

PridCor's Strategic Focus on Combination Antiviral Therapies

Recent clinical investigations have explored innovative combination therapy approaches for Long COVID treatment, with emerging evidence from both traditional medicine and oxygen-based interventions. These studies represent early-stage research efforts to address the complex, multi-system nature of post-acute sequelae of COVID-19.

• Japanese Traditional Medicine (JTM/Kampo) combination therapy demonstrated significant improvements in health-related quality of life in a single-center prospective observational study (October 2021-August 2024) involving 112 patients with symptoms persisting beyond 28 days from COVID-19 onset

• Kamikihito and saikokeishito combination regimen was administered to 20 patients and showed superior efficacy compared to single-agent JTM therapy, with multivariate regression analysis revealing odds ratios of 5.4 for all patients and 6.1 specifically for the brain fog subgroup

• Brain fog-specific patient outcomes showed median health-related quality of life scores increasing from 0.677 at baseline to 0.750 at 3 months (p < 0.005), representing clinically meaningful improvement in this challenging symptom domain

• Hyperbaric Oxygen Therapy (HBOT) emerged as a promising combination approach based on a comprehensive literature review spanning January 2021 to October 2025, analyzing 21 studies including randomized controlled trials and systematic reviews

• HBOT treatment benefits encompassed improvements across multiple symptom domains including quality of life, fatigue, cognition, neuropsychiatric symptoms, and cardiopulmonary functions, with demonstrated safety profile across reviewed studies

• Research validation requirements indicate that both JTM combination therapy and HBOT require larger-scale randomized controlled trials to establish definitive treatment protocols, optimal dosing regimens, and standardized post-treatment evaluation criteria

IMC-1 and IMC-2: Expanding the Antiviral Pipeline

Based on the available literature, IMC-1 has been investigated beyond Long COVID applications, while IMC-2 appears limited to laboratory research contexts. The clinical development of IMC-1 demonstrates potential for treating additional conditions with similar underlying viral reactivation mechanisms.

Addressing the Significant Unmet Needs in Long COVID

Current treatment approaches for Long COVID face substantial obstacles that limit their effectiveness and accessibility. The condition, characterized as a post-acute sequelae of SARS-CoV-2 (PASC) with medically unexplained symptoms, represents a newly recognized infection-associated chronic condition causing disability in affected individuals. The complexity of Long COVID necessitates multidisciplinary treatment approaches, yet significant gaps remain in our therapeutic capabilities.

• Absence of curative therapies: No cure exists for the tens of millions of people believed to be experiencing Long COVID, leaving patients with symptomatic management as the primary treatment option.

• Limited pharmaceutical industry engagement: Industry participation in developing targeted therapeutics for Long COVID has been insufficient, constraining the pipeline of potential treatment options.

• Incomplete understanding of disease mechanisms: Substantial research gaps persist in fully comprehending the pathophysiology and long-term effects of Long COVID, hampering the development of evidence-based interventions.

• Inadequate funding and investment: Progress toward preventing and curing Long COVID requires deep and sustained investment by funders and industry that has not yet materialized at the necessary scale.

• Persistent health equity disparities: Significant gaps in equitable care continue across racial and socioeconomic lines, with communities of color facing particular challenges in accessing diagnosis, treatment, and comprehensive care for Long COVID.

• Healthcare system preparedness deficits: The complexity of Long COVID management demands coordinated multidisciplinary approaches that many healthcare systems are not adequately equipped to provide consistently.

PridCor's Antiviral Portfolio: Reshaping Chronic Disease Treatment

PridCor Therapeutics' recent acquisition of a global antiviral asset portfolio signals a bold strategic pivot, aiming to redefine the treatment landscape for a range of infection-associated chronic illnesses (IACIs). This move is particularly impactful given the substantial global burden of conditions like Long COVID and fibromyalgia, both of which currently lack approved, targeted therapies. The core of PridCor's strategy lies in addressing viral reactivation and persistence, a mechanism increasingly implicated as a driver for these debilitating chronic states.

The portfolio's flagship assets, IMC-1 and IMC-2, represent significant advancements. IMC-1, a fixed-dose combination targeting suspected herpes virus reactivation, has already demonstrated efficacy and a favorable safety profile in a Phase 2 trial for fibromyalgia, significantly reducing pain, improving functioning, and alleviating fatigue. This success not only validates the therapeutic approach but also positions IMC-1 as a Phase 3-ready candidate, potentially offering a novel treatment option for millions suffering from this complex syndrome.

For Long COVID, IMC-2 offers a promising avenue. Pilot evidence from an open-label case series suggests that IMC-2, particularly when combined with an existing antiviral like Paxlovid, can lead to statistically significant and durable improvements in symptoms such as fatigue, brain fog, and dysautonomia. This combination approach, targeting both SARS-CoV-2 persistence and herpesvirus reactivation, highlights a pragmatic strategy to leverage established antivirals while developing a new therapeutic.

However, the path forward is not without its considerations. While the pilot data for IMC-2 in Long COVID is encouraging, the transition from a small, open-label study to larger, controlled Phase 2b/3 trials will be critical, as early results do not always translate. Similarly, while the viral reactivation hypothesis for fibromyalgia is supported by IMC-1's data, its broader applicability across diverse patient populations will be a key area of focus. PridCor's ability to navigate these clinical and regulatory hurdles, while potentially forging partnerships for combination therapies, will determine its success in establishing a leadership position in this emerging and critical therapeutic area. This strategic acquisition positions PridCor to potentially unlock new treatment paradigms for chronic conditions driven by viral persistence.